Literature DB >> 22573503

Leukocytosis as an important risk factor for arterial thrombosis in WHO-defined early/prefibrotic myelofibrosis: an international study of 264 patients.

Veronika Buxhofer-Ausch1, Heinz Gisslinger, Jürgen Thiele, Bettina Gisslinger, Hans-Michael Kvasnicka, Leonhard Müllauer, Sophie Frantal, Alessandra Carobbio, Francesco Passamonti, Elisa Rumi, Marco Ruggeri, Francesco Rodeghiero, Maria L Randi, Irene Bertozzi, Alessandro M Vannucchi, Elisabetta Antonioli, Guido Finazzi, Naseema Gangat, Ayalew Tefferi, Tiziano Barbui.   

Abstract

We aimed to determine risk factors for thrombotic events in early/prefibrotic myelofibrosis diagnosed according to the World Health Organization criteria. Multivariate Cox regression analysis was calculated on a total number of 264 patients derived from an international database. After a median follow-up of 6.28 years, 42 (15.9%) patients experienced arterial (n = 31) or venous thrombosis (n = 11). A higher leukocyte count correlated with an increased risk for total thrombosis and in particular, with an increased risk for arterial thrombosis (P = 0.005, HR 1.15 and P = 0.047, HR 1.12, respectively). A platelet count above 870 × 10⁹/L was associated with a lower risk for total thrombosis and also for venous thrombosis (P = 0.022, HR 0.44 and P = 0.027, HR 0.19). Moreover, a lower hemoglobin level was associated with an increased risk for venous thrombosis (P = 0.007, HR 0.59). Our data indicate that leukocytosis is a prominent risk factor for thrombosis in early/prefibrotic MF.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2012        PMID: 22573503     DOI: 10.1002/ajh.23217

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  15 in total

Review 1.  Thrombosis in Philadelphia negative classical myeloproliferative neoplasms: a narrative review on epidemiology, risk assessment, and pathophysiologic mechanisms.

Authors:  Somedeb Ball; Kyaw Zin Thein; Abhishek Maiti; Kenneth Nugent
Journal:  J Thromb Thrombolysis       Date:  2018-05       Impact factor: 2.300

Review 2.  The underappreciated risk of thrombosis and bleeding in patients with myelofibrosis: a review.

Authors:  Devendra Kc; Lorenzo Falchi; Srdan Verstovsek
Journal:  Ann Hematol       Date:  2017-08-14       Impact factor: 3.673

Review 3.  SOHO State-of-the-Art Update and Next Questions: MPN.

Authors:  Prithviraj Bose; Jason Gotlib; Claire N Harrison; Srdan Verstovsek
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2018-01

Review 4.  Risk Factors for and Management of MPN-Associated Bleeding and Thrombosis.

Authors:  Karlyn Martin
Journal:  Curr Hematol Malig Rep       Date:  2017-10       Impact factor: 3.952

5.  From Budd-Chiari syndrome to acquired von Willebrand syndrome: thrombosis and bleeding complications in the myeloproliferative neoplasms.

Authors:  Brady L Stein; Karlyn Martin
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

6.  Symptom burden profile in myelofibrosis patients with thrombocytopenia: Lessons and unmet needs.

Authors:  Allison H Scotch; Heidi Kosiorek; Robyn Scherber; Amylou C Dueck; Stefanie Slot; Sonja Zweegman; Peter A W Te Boekhorst; Suzan Commandeur; Harry Schouten; Federico Sackmann; Ana Kerguelen Fuentes; Dolores Hernández-Maraver; Heike L Pahl; Martin Griesshammer; Frank Stegelmann; Konstanze Döhner; Thomas Lehmann; Karin Bonatz; Andreas Reiter; Francoise Boyer; Gabriel Etienne; Jean-Christophe Ianotto; Dana Ranta; Lydia Roy; Jean-Yves Cahn; Claire N Harrison; Deepti Radia; Pablo Muxi; Norman Maldonado; Carlos Besses; Francisco Cervantes; Peter L Johansson; Tiziano Barbui; Giovanni Barosi; Alessandro M Vannucchi; Chiara Paoli; Francesco Passamonti; Bjorn Andreasson; Maria L Ferrari; Alessandro Rambaldi; Jan Samuelsson; Gunnar Birgegard; Zhijian Xiao; Zefeng Xu; Yue Zhang; Xiujuan Sun; Junqing Xu; Jean-Jacques Kiladjian; Peihong Zhang; Robert Peter Gale; Ruben A Mesa; Holly L Geyer
Journal:  Leuk Res       Date:  2017-10-14       Impact factor: 3.156

7.  Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial.

Authors:  Heinz Gisslinger; Mirjana Gotic; Jerzy Holowiecki; Miroslav Penka; Juergen Thiele; Hans-Michael Kvasnicka; Robert Kralovics; Petro E Petrides
Journal:  Blood       Date:  2013-01-11       Impact factor: 22.113

8.  Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms.

Authors:  Ofir Wolach; Rob S Sellar; Kimberly Martinod; Deya Cherpokova; Marie McConkey; Ryan J Chappell; Alexander J Silver; Dylan Adams; Cecilia A Castellano; Rebekka K Schneider; Robert F Padera; Daniel J DeAngelo; Martha Wadleigh; David P Steensma; Ilene Galinsky; Richard M Stone; Giulio Genovese; Steven A McCarroll; Bozenna Iliadou; Christina Hultman; Donna Neuberg; Ann Mullally; Denisa D Wagner; Benjamin L Ebert
Journal:  Sci Transl Med       Date:  2018-04-11       Impact factor: 17.956

9.  Persistent neutrophilia is a marker for an increased risk of venous thrombosis.

Authors:  Margarita Kushnir; Hillel W Cohen; Henny H Billett
Journal:  J Thromb Thrombolysis       Date:  2016-11       Impact factor: 2.300

Review 10.  Personalized management of essential thrombocythemia-application of recent evidence to clinical practice.

Authors:  A Tefferi; T Barbui
Journal:  Leukemia       Date:  2013-04-05       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.